NextCure to Present at 24th Annual Needham Virtual Healthcare Conference
NextCure (Nasdaq: NXTC), a clinical-stage biopharmaceutical company focused on cancer therapy development, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The presentation is scheduled for Thursday, April 10th, at 8:45 am ET.
Investors and interested parties can access a live audio webcast through the Investors section of NextCure's website. The presentation recording will remain available on the company's website for 30 days following the event.
NextCure (Nasdaq: NXTC), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie per il cancro, ha annunciato la sua partecipazione alla 24ª Conferenza Virtuale Annuale di Needham sulla Salute. La presentazione è programmata per giovedì 10 aprile, alle 8:45 ET.
Gli investitori e le parti interessate possono accedere a una diretta audio tramite la sezione Investitori del sito web di NextCure. La registrazione della presentazione rimarrà disponibile sul sito dell'azienda per 30 giorni dopo l'evento.
NextCure (Nasdaq: NXTC), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de terapias contra el cáncer, ha anunciado su participación en la 24ª Conferencia Virtual Anual de Salud de Needham. La presentación está programada para jueves 10 de abril, a las 8:45 am ET.
Los inversores y partes interesadas pueden acceder a una transmisión de audio en vivo a través de la sección de Inversores en el sitio web de NextCure. La grabación de la presentación estará disponible en el sitio web de la empresa durante 30 días después del evento.
NextCure (Nasdaq: NXTC), 암 치료 개발에 중점을 둔 임상 단계의 생명공학 회사가 제24회 니드햄 가상 건강 회의에 참가한다고 발표했습니다. 발표는 4월 10일 목요일, 오전 8:45 ET로 예정되어 있습니다.
투자자 및 관심 있는 분들은 NextCure 웹사이트의 투자자 섹션을 통해 생중계 오디오 웹캐스트에 접속할 수 있습니다. 발표 녹화는 이벤트 종료 후 30일 동안 회사 웹사이트에서 제공됩니다.
NextCure (Nasdaq: NXTC), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies contre le cancer, a annoncé sa participation à la 24e Conférence Virtuelle Annuelle de Needham sur la Santé. La présentation est prévue pour jeudi 10 avril, à 8h45 ET.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire audio en direct via la section Investisseurs du site Web de NextCure. L'enregistrement de la présentation restera disponible sur le site de l'entreprise pendant 30 jours après l'événement.
NextCure (Nasdaq: NXTC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Krebstherapien konzentriert, hat seine Teilnahme an der 24. jährlichen virtuellen Gesundheitskonferenz von Needham bekannt gegeben. Die Präsentation ist für Donnerstag, den 10. April, um 8:45 Uhr ET geplant.
Investoren und Interessierte können über den Investorenbereich der Website von NextCure auf einen Live-Audio-Webcast zugreifen. Die Aufzeichnung der Präsentation bleibt 30 Tage nach der Veranstaltung auf der Website des Unternehmens verfügbar.
- None.
- None.
BELTSVILLE, Md., April 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, at 8:45 am ET.
A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. A replay of the webcast will be available after the event and archived on the website for 30 days.
About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including antibody-drug conjugates. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. http://www.nextcure.com
Cautionary Statement Regarding Forward-Looking Statements
Some of the statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to funding for our operations, objectives and expectations for our business, operations and financial performance and condition, including the progress and results of clinical trials, development plans and upcoming milestones regarding our therapies. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “continue,” “could,” “should,” “due,” “estimate,” “expect,” “intend,” “hope,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “target,” “towards,” “forward,” “later,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language.
Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure’s limited operating history and not having any products approved for commercial sale; NextCure’s history of significant losses; NextCure’s need and ability to obtain additional financing on acceptable terms or at all; risks related to clinical development, marketing approval and commercialization; NextCure’s ability to maintain listing of its common stock on the Nasdaq Global Select Market; and NextCure’s dependence on key personnel. More detailed information on these and additional factors that could affect NextCure’s actual results are described under the heading “Risk Factors” in NextCure’s most recent Annual Report on Form 10-K and in NextCure’s other filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, even if expectations change.
Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com
FAQ
When is NextCure (NXTC) presenting at the Needham Healthcare Conference 2025?
How can investors access NextCure's (NXTC) Needham Conference presentation?
How long will NextCure's (NXTC) Needham Conference presentation be available for replay?
What type of company is NextCure (NXTC) and what is their focus?
